POLQ is altered in 7.35% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

POLQ is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

POLQ is altered in 6.85% of diffuse large B-cell lymphoma patients [3].

POLQ is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

POLQ is altered in 6.81% of urothelial carcinoma patients [3].

POLQ is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

POLQ is altered in 6.07% of malignant solid tumor patients [3].

POLQ is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

POLQ is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].